Brief: Zhaoke Ophthalmology Says Ind Application Of Nvk-002 Approved By CDE Of NMPA Of China
Sept 27 (Reuters) - Zhaoke Ophthalmology Ltd 6622.HK :
* IND APPLICATION OF NVK-002 FOR PHASE III CLINICAL TRIAL IN
CHINA
APPROVED BY CENTER FOR DRUG EVALUATION OF NMPA OF CHINA
Further company coverage: 6622.HK
((reuters.briefs@thomsonreuters.com;))
Recent news on Zhaoke Ophthalmology
See all newsBrief: Zhaoke Ophthalmology Says Its Facility In Guangzhou Obtains GMP Certification From Australia's TGA
China's Zhaoke Ophthalmology H1 revenue rises
Brief: Zhaoke Ophthalmology Says Yuvezzitm Approved By Macau Pharmaceutical Administration Bureau
Brief: Zhaoke Ophthalmology Enters Into Definitive Agreement For Acquisition Of Global Rights To NVK002
Brief: Zhaoke Ophthalmology Says Yuvezzitm Approved For Use At Boao Super Hospital